CRISPR Therapeutics, MGH Partner to Develop T-Cell Cancer Therapies

06:28 EDT 22 Aug 2017 | Genetic Engineering News

CRISPR Therapeutics and Massachusetts General Hospital Cancer Center (MGHCC) said today they will develop novel T cell therapies for blood and solid tumors by using CRISPR/Cas9 gene editing to improve upon current T cell treatments, through a collaboration whose value was not disclosed. CRISPR Therapeutics said the collaboration represents its latest step toward developing immuno-oncology treatments. The company in February named Jon Terrett, Ph.D. to lead its unit focused on advancing to clinical phases immuno-oncology therapies based on CRISPR (clustered regularly interspaced short palindromic repeats).  Four months later, in June, CRISPR Therapeutics signed a service agreement with MaSTherCell, a full-service contract development and manufacturing organization (CDMO) and wholly-owned subsidiary of Orgenesis, to develop and manufacture allogeneic CAR-T therapies. Those therapies include CRISPR Therapeutics’ wholly-owned lead immuno-oncology program targeting CD19 positive malignancies, CTX101, now in its IND-enabling phase. CTX101 uses the company’s gene-editing technology to make targeted modifications ...

Original Article: CRISPR Therapeutics, MGH Partner to Develop T-Cell Cancer Therapies


More From BioPortfolio on "CRISPR Therapeutics, MGH Partner to Develop T-Cell Cancer Therapies"

Quick Search


Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...